The Innovation | Virtual Collection—Killing Cancer (v3) 癌症专辑3.0

Figure 1 Summary of Publishing (2020—2022)

图1 出版概览(2020—2022年)

Introduction: The Innovation has published 300 articles from 2020 to 2022 (Figure 1).  The authors come from 49 countries and articles belong to 9 categories (Figure 2), which have been cited by researchers from 113 countries (Source: Web of Science). The Innovation is a multidisciplinary journal covering all natural science fields. To facilitate readers to refer to articles in a specific field, Editorial Team integrates the contents from different Issues to make this Virtual Collection. 

引言：从2020到2022，The Innovation出版三卷十三期共300篇文章（图1），作者来自49个国家。这些文章分布在9个栏目（图2），已被113个国家作者引用（数据源: Web of Science）。The Innovation是综合性英文期刊，发文内容涵盖所有自然科学领域。为方便读者查看出版的某领域文章，编辑部整合这两年不同刊次的相关内容，陆续推送Virtual Collection（虚拟专辑）……在本刊发表的文章，同时在微信公众号上进行“科普化解读”——尽可能让更多人懂得文章的主旨和亮点：传播科学知识，传承科学素养；和您一起理解科技创新的最新进展与突破！2020年-2021年，出版周期为季刊；2022年-2023年，出版周期为双月刊（出版月份：1/3/5/7/9/11）

Figure 2 Categories of Publishing (2020—2022)图2 文章全貌(2020—2022年)

 About Killing Cancer (v3) 

癌症专辑3.0

Cancer is a complicated disease believed to be caused by genetic mutations. Numerous scientists and physicians have been making history in cancer research and clinical management. Now we are in the era of precision medicine and it is promising to kill cancer via multidisciplinary collaboration in near future.

癌症是基因突变导致的复杂疾病。前赴后继的科学家和医学家在癌症研究和临床治疗上不断创造历史……当前处在精准医学时代，多学科团队的精诚合作将有望为人类最终战胜癌症带来福音。本次虚拟专辑收录与Cancer相关的，News & Buzz 1篇，Editorial 1篇，Translational Patent 1篇，Report 4篇，Article 3篇，Commentary 4篇，Review 13篇；共计27篇。

 Section 1

News & Buzz

China enters CAR-T cell therapy era

 Section 2

Editorial

Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges

 Section 3

Translational Patent

Innovative Irinotecan-loaded Nanomicelles will Enter Phase I Clinical Trial in 2021

 Section 4

Reports

Assessment of Spinal Tumor Treatment Using Implanted 3D-Printed Vertebral Bodies with Robotic Stereotactic Radiotherapy

DCLK1 autoinhibition and activation in tumorigenesis

Toripalimab in advanced biliary tract cancer

Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer

 Section 5

Articles

clusterProfiler 4.0: A universal enrichment tool for interpreting omics data

Profiling of immune features to predict immunotherapy efficacy

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

 Section 6

Commentaries

On the ultimate finishing line of the Human Genome Project

Delta.AR: An augmented reality-based visualization platform for 3D genome

Opening up the black box of human cell plasticity

Cancer susceptibility genes: update and systematic perspectives

 Section 7

Reviews

Therapy of primary liver cancer

Overcoming resistance to drugs targeting KRAS^G12C mutation

Insights into hepatitis B Virus DNA integration-55 years after virus discovery

Current status and future perspective of immunotherapy in gastrointestinal cancers

RNA m⁶A modification in cancers: molecular mechanisms and potential clinical applications

Small molecular NIR-II fluorophores for cancer phototheranostics

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Applications and potentials of nanopore sequencing in the (epi)genome and (epi)transcriptome era

Greenspace and human health: An umbrella review

Nanotechnology-enhanced immunotherapy for metastatic cancer

Nanotechnology for cardiovascular diseases

Circulating cell-free DNA for cancer early detection

Single-cell technologies: From research to application

期刊简介

扫二维码 ｜ 关注期刊官微

The Innovation是一本由青年科学家与Cell Press于2020年共同创办的综合性英文学术期刊：向科学界展示鼓舞人心的跨学科发现，鼓励研究人员专注于科学的本质和自由探索的初心。作者来自全球50个国家；已被116个国家作者引用；每期1/4-1/3通讯作者来自海外。目前有195位编委会成员，来自21个国家；50%编委来自海外；包含1位诺贝尔奖获得者，33位各国院士；领域覆盖全部自然科学。The Innovation已被DOAJ，ADS，Scopus，PubMed，ESCI，INSPEC，EI等数据库收录。秉承“好文章，多宣传”理念，The Innovation在海内外各平台推广作者文章。

期刊官网1（Owner）：

www.the-innovation.org

期刊官网2（Publisher）：

www.cell.com/the-innovation/home

期刊投稿（Submission）：

www.editorialmanager.com/the-innovation

商务合作（Marketing）：

[e-mail]

Logo｜期刊标识

See the unseen & change the unchanged

创新是一扇门，我们探索未知；  

创新是一道光，我们脑洞大开；  

创新是一本书，我们期待惊喜；  

创新是一个“1”，我们一路同行。